Artivion, Inc. (NYSE:AORT) SVP Jean F. Holloway Sells 472 Shares

Artivion, Inc. (NYSE:AORT - Get Free Report) SVP Jean F. Holloway sold 472 shares of Artivion stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $25.29, for a total transaction of $11,936.88. Following the sale, the senior vice president now directly owns 172,743 shares of the company's stock, valued at $4,368,670.47. This represents a 0.27 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Artivion Stock Down 2.4 %

AORT traded down $0.59 during trading on Monday, hitting $23.59. The company had a trading volume of 849,479 shares, compared to its average volume of 257,016. The company has a market capitalization of $991.87 million, a PE ratio of -1,179.45 and a beta of 1.79. Artivion, Inc. has a one year low of $19.11 and a one year high of $32.33. The firm's 50-day moving average price is $29.03 and its 200 day moving average price is $27.82. The company has a quick ratio of 1.33, a current ratio of 1.88 and a debt-to-equity ratio of 0.71.

Artivion (NYSE:AORT - Get Free Report) last posted its quarterly earnings data on Monday, February 24th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of $0.12 by ($0.51). The company had revenue of $97.31 million during the quarter, compared to the consensus estimate of $100.82 million. Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. As a group, equities analysts expect that Artivion, Inc. will post 0.37 earnings per share for the current year.

Remove Ads

Institutional Investors Weigh In On Artivion

Several institutional investors have recently added to or reduced their stakes in the stock. Squarepoint Ops LLC lifted its position in Artivion by 30.8% in the 4th quarter. Squarepoint Ops LLC now owns 35,707 shares of the company's stock valued at $1,021,000 after acquiring an additional 8,404 shares in the last quarter. Tidal Investments LLC lifted its position in Artivion by 14.5% during the 4th quarter. Tidal Investments LLC now owns 179,806 shares of the company's stock worth $5,141,000 after buying an additional 22,804 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in Artivion during the 4th quarter worth about $64,000. Point72 Asset Management L.P. bought a new stake in Artivion during the 4th quarter worth about $5,573,000. Finally, ProShare Advisors LLC lifted its position in Artivion by 44.7% during the 4th quarter. ProShare Advisors LLC now owns 11,924 shares of the company's stock worth $341,000 after buying an additional 3,683 shares in the last quarter. 86.37% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on AORT. Stifel Nicolaus reduced their price target on shares of Artivion from $33.00 to $30.00 and set a "buy" rating on the stock in a research report on Tuesday, February 25th. JMP Securities reissued a "market outperform" rating and set a $33.00 price target on shares of Artivion in a research report on Tuesday, December 10th. Finally, Needham & Company LLC reduced their price target on shares of Artivion from $34.00 to $32.00 and set a "buy" rating on the stock in a research report on Tuesday, February 25th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $31.40.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.